- Home
- GSAT vs PRAX Comparison
GSAT vs PRAX Comparison
Compare GSAT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSAT | PRAX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.8B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GSAT | PRAX |
|---|---|---|
| Price | $60.55 | $312.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $52.75 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 718.1K | 616.0K |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $262,202,000.00 | $7,463,000.00 |
| Revenue This Year | $10.93 | N/A |
| Revenue Next Year | $10.72 | $14,827.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.54 | ★ 364.98 |
| 52 Week Low | $17.24 | $26.70 |
| 52 Week High | $74.88 | $326.91 |
Technical Indicators
Market Signals| Indicator | GSAT | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 66.64 |
| Support Level | $61.22 | $266.93 |
| Resistance Level | $65.75 | $306.16 |
| Average True Range (ATR) | 4.34 | 17.82 |
| MACD | -0.32 | -1.32 |
| Stochastic Oscillator | 25.48 | 78.28 |
Price Performance
Historical ComparisonAbout GSAT Globalstar Inc.
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.